Meclofenamate Treatment of Recurrent Idiopathic Nephrotic Syndrome With Focal Segmental Glomerulosclerosis After Renal Transplantation

VICENTE E. TORRES, JORGE A. VELOSA, KEITH E. HOLLEY, PETER P. FROHNERT, HORST ZINCKE, SYLVESTER STERIOFF

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Recurrent corticosteroid-resistant nephrotic syndrome with focal segmental glomerulosclerosis (FSGS) caused the failure of a first renal allograft in a 41-year-old man. Recurrence of the nephrotic syndrome in the second renal allograft was successfully controlled by the administration of meclofenamate, and the renal function has remained stable for 2½ years. No accepted treatment is available for corticosteroid-resistant nephrotic syndrome with FSGS. This report suggests that administration of meclofenamate might be beneficial in some patients with corticosteroid-resistant nephrotic syndrome and FSGS. Because of the potential side effects, however, careful supervision of this therapy is of the utmost importance.

Original languageEnglish (US)
Pages (from-to)146-152
Number of pages7
JournalMayo Clinic proceedings
Volume59
Issue number3
DOIs
StatePublished - Jan 1 1984

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Meclofenamate Treatment of Recurrent Idiopathic Nephrotic Syndrome With Focal Segmental Glomerulosclerosis After Renal Transplantation'. Together they form a unique fingerprint.

  • Cite this